## bs-4770R

## [ Primary Antibody ]

## CD133 Rabbit pAb



www.bioss.com.cn sales@bioss.com.cn techsupport@bioss.com.cn 400-901-9800

— DATASHEET ————			
Host: Rabbit	<b>lsotype:</b> IgG	Applications: WB (1:500-2000)	
Clonality: Polyclonal		Flow-Cyt (1µg/Test)	
GenelD: 8842	SWISS: 043490	Reactivity: Human, Mouse	
Target: CD133		(predicted: Rat)	
Immunogen: KLH conjugated synthetic peptide derived from human CD133: 508-552/865. < Extracellular >		Predicted <sub>95 kDa</sub> MW.:	
Purification: affinity purified by Protein A			
Concentration: 1mg/ml		Subcellular Location: Cell membrane	
<b>Storage:</b> 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.			
<b>Background:</b> This gene encodes a protein localizes to on adult stem cells, stem cell properties	a pentaspan transmembrane glycoprotein. T membrane protrusions and is often expresse where it is thought to function in maintainin s by suppressing differentiation. Mutations in	he ed g	

- VALIDATION IMAGES -



Sample: SP2/0 Cell (Mouse) Lysate at 40 ug Colon carcinoma (Human) Lysate at 40 ug Primary: Anti-CD133 (bs-4770R) at 1/300 dilution Secondary: HRP conjugated Goat-Anti-rabbit IgG (bs-0295G-HRP) at 1/5000 dilution Predicted band size: 95 kD Observed band size: 95/120 kD



this gene have been shown to result in retinitis pigmentosa and Stargardt disease. Expression of this gene is also associated with several types of cancer. This gene is expressed from at least five alternative promoters that are expressed in a tissue-dependent manner. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Mar 2009]

> Sample: Lane 1: SP2/0 (Mouse) Cell Lysate at 30 ug Lane 2: Lovo (Human) Cell Lysate at 30 ug Lane 3: SW480 (Human) Cell Lysate at 30 ug Lane 4: Uterus (Mouse) Lysate at 40 ug Primary: Anti-CD133 (bs-4770R) at 1/300 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 110 kD Observed band size: 115 kD



Blank control:Mouse kidney. Primary Antibody (green line): Rabbit Anti-CD133 antibody (bs-4770R) Dilution: 2µg /10^6 cells; Isotype Control Antibody (orange line): Rabbit IgG . Secondary Antibody : Goat anti-rabbit IgG-AF488 Dilution: 1µg /test. Protocol The cells were incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.



The blue histogram is unstained cells(HepG 2). The Orange histogram is cells stained with Rabbit IgG/FITC (bs-0295P-FITC) The green histogram is cells stained with Rabbit Anti-CD133/FITC Conjugated antibody (bs-4770R-FITC). Isotype control: Cell lines treated with Rabbit IgG/FITC (bs-0295P-FITC) instead of the primary antibody to confirm that primary antibody binding is 2µg/5µg/1µg in 100µL 1 X PBS containing 0.5% BSA.

## - SELECTED CITATIONS -

- [IF=6.7] Ruiqian Sun. et al. Astragali Radix-Curcumae Rhizoma herb pair reduces the stemness of colorectal cancer cells through HIF-2α/β-catenin pathway. PHYTOMEDICINE. 2024 Sep;132:155824 WB ;MOUSE. 38941816
- [IF=5.587] Qi et al. Targeting the Wnt-Regulatory Protein CTNNBIP1 by microRNA-214 Enhances the Stemness and Self-Renewal of Cancer Stem-Like Cells in Lung Adenocarcinomas. (2015) Stem.Cells. 33(12):3423-36 IHC,IF ;Human. 26299367
- [IF=3.811] Sun Z et al. Glioblastoma Stem Cell-Derived Exosomes Enhance Stemness and Tumorigenicity of Glioma Cells by Transferring Notch1 Protein. Cell Mol Neurobiol. 2019 Dec 18. WB ;Human&Mouse. 31853695
- [IF=4.486] Wang L et al. Lung CSC derived exosomal miR 210 3p contributes to a pro metastatic phenotype in lung cancer by targeting FGFRL1. J Cell Mol Med. 2020 Jun;24(11):6324-6339. WB,IF ;Human. 32396269
- [IF=4.432] Yang Yang. et al. PT109, a novel multi-kinase inhibitor suppresses glioblastoma multiforme through cell reprogramming: Involvement of PTBP1/PKM1/2 pathway. Eur J Pharmacol. 2022 Apr;920:174837 WB ;Human. 10.1016/j.ejphar.2022.174837